Drugs / HEC88473
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05943886 | Aug 2021 → Feb 2023 | obesity disorder, type 2 diabetes mellitus | Dongguan HEC Biopharmaceutical R&D Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04829123 | May 2021 → Mar 2022 | metabolic dysfunction-associated steatohepatitis | Dongguan HEC Biopharmaceutical R&D Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07616037 | Jun 2026 → Jun 2027 expected | polycystic ovary syndrome | Shanghai Zhongshan Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06148649 | Dec 2023 → Feb 2025 | type 2 diabetes mellitus | Dongguan HEC Biopharmaceutical R&D Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HEC88473 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04829123 ↗ |
| Action | Activate | “HEC88473 is a novel long-acting dual agonist of glucagon-like peptide 1 (GLP-1) and fibroblast growth factor 21 (FGF21) receptors.” PMID 40175670 ↗ Apr 2025 |
| Modality | Protein / enzyme biologic | “It is a Fc fusion protein containing a fibroblast growth factor 21 and a GLP-1 moiety, fused to the N-terminal and C-terminal of the Fc fragment, respectively.” PMID 40175670 ↗ Apr 2025 |
| Route | Subcutaneous | “administered by subcutaneous injection” NCT04829123 ↗ |